ArticleAIDS (London, England)2012
HIV infection and glycemic response to newly initiated diabetic medical therapy.
Article in AIDS (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa.Progress in cardiovascular diseasesPooled it
- The effect of HIV infection on glycaemia and renal function in type 2 diabetic patients.PloS one · 2018Trial
- Trial
- Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- miR-23a-3p as a Biomarker Associated with Prediabetes in People Living with HIV: An Integrative Analysis of Inflammatory, Metabolic, and Insulin Resistance Signatures.International journal of molecular sciences · 2026Article
- Diabetes mellitus among HIV patients on ART at Woldia comprehensive specialized hospital, Northeast Ethiopia.Scientific reports · 2025Article
- The prevalence of hyperglycemia and its impact on mortality among people living with HIV in Georgia.PloS one · 2022Article
- Diabetes mellitus control in a large cohort of people with HIV in care-Washington, D.C.AIDS care · 2021Article
- Diagnosis, risk factors and management of diabetes mellitus in HIV-infected persons in France: A real-life setting study.PloS one · 2021Article
- Pilot test of an educational intervention to improve self-management of diabetes in persons living with HIV.Pilot and feasibility studies · 2019Article
- Impact of a medical home model on costs and utilization among comorbid HIV-positive Medicaid patients.The American journal of managed care · 2018Article
- Immune reconstitution in ART treated, but not untreated HIV infection, is associated with abnormal beta cell function.PloS one · 2018Article
- Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans.Diabetes care · 2017Article
- Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010.BMJ open diabetes research & care · 2017Article
- Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.Current HIV/AIDS reports · 2016Review
- Identification of type 2 diabetes subgroups through topological analysis of patient similarity.Science translational medicine · 2015Article
- Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults.AIDS research and human retroviruses · 2015Article
- Metabolic consequences of HIV: pathogenic insights.Current HIV/AIDS reports · 2014Review
- Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008-2015.Progress in cardiovascular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesType 2 diabetes (DM2) is increasingly common in HIV-infected individuals. Antiretroviral agents and chronic inflammation may adversely affect glycemic control. However, little is known about the effectiveness of diabetic medical therapy in HIV-infected patients. The objective of this study was to compare the effectiveness of initial diabetic medical therapy in patients with and without HIV infection.
designA retrospective cohort study was conducted among adults with DM2 initiating diabetic medications within the Centers for AIDS Research Network of Integrated Clinical Systems cohort.
methodsGeneralized estimating equations were used to compare changes in hemoglobin A1c (HbA1c) through the year after initiation of therapy, controlling for baseline HbA1c and demographic and clinical covariates.
resultsTwo hundred and eighty-six HIV-infected patients and 858 age and sex-matched HIV-uninfected patients initiated diabetic medications during the study period. Overall, patients had an adjusted absolute mean reduction in HbA1c of 1.04% [95% confidence interval (CI) -0.87 to -1.22] during the first year of therapy. HIV-infected patients achieved significantly smaller reductions in HbA1c, with an absolute mean difference of -0.17% (95% CI -0.28 to -0.06; P = 0.003). On subanalyses, HIV-infected patients on a protease inhibitor-based regimen had significantly smaller reductions in HbA1c compared to HIV-uninfected patients (adjusted absolute difference -0.21%, 95% CI -0.35 to -0.08; P = 0.002).
conclusionPatients with HIV infection who initiate diabetic medical therapy achieve smaller reductions in HbA1c than patients without HIV infection in the course of routine clinical care. This less robust response may in part be related to use of antiretrovirals that exacerbate insulin resistance, specifically protease inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.